Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Compassionate use of satralizumab in neuromyelitis optica spectrum disorder
jRCT2080225027Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of satralizumab in neuromyelitis optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Safety of satralizumab. Started Jan 2020; status: completed.
02
Drugs
satralizumab
03
Conditions
neuromyelitis optica (NMO)Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on jRCT2080225027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225027.